List clinical trials by disease

Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.

Searched for: Lymphoma, Hodgkin. 12 results shown below.
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Complete title: A Phase II Trial of High-dose 90Y-Ibritumomab Tiuxetan (anti-CD20) followed by Fludarabine and Low-dose Total Body Irradiation and HLA-matched Allogeneic Hematopoietic Transplantation for Patients with Relapsed or Refractory Aggressive B-cell Lymphoma

Principal Investigator: Ajay Gopal, MD

Study Number: 2398.00

Phase: II



Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)
Complete title: A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients with Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

Principal Investigator: Ajay Gopal, MD

Study Number: 9111

Phase: I/II



Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Complete title: Transplantation of Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen

Principal Investigator: Ann Dahlberg

Study Number: 2010.00

Phase: II



Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Complete title: A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD after Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation – A Multi-Center Trial

Principal Investigator: Brenda Sandmaier, MD

Study Number: 2206.00

Phase: II



Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Complete title: Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT using Related, HLA-Haploidentical Donors for Patients with High-Risk lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Principal Investigator: Mohamed Sorror, MD, MSc

Study Number: 2241.00

Phase: II



Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Complete title: Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Principal Investigator: Rachel Salit

Study Number: 2372.00

Phase: II



Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Nonmyeloablative Hematopoietic Cell Transplantation

Principal Investigator: Marco Mielcarek, MD

Study Number: 2546.00

Phase: II



Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)
Complete title: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies

Principal Investigator: Rachel Salit

Study Number: 2580.00

Phase: III



HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
Complete title: A Clinical Trial of Gene-Modified Stem Cells to Generate HIV-Resistant Cells in Conjunction with Standard Chemotherapy for Treatment of Lymphoma in Patients with HIV Infection

Principal Investigator: Ann Woolfrey, MD

Study Number: 2673.00

Phase: I



Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Complete title: A Phase II Randomized, Placebo -Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant

Principal Investigator: Joshua Hill

Study Number: 9733

Phase: II



Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Complete title: A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

Principal Investigator: Julie Park, MD

Study Number: ADVL1412

Phase: I/II



Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma
Complete title: AHOD1331, A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Principal Investigator: Doug Hawkins, MD

Study Number: AHOD1331

Phase: III



Search all clinical trials

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials